BRAF and cancer: Notably, Patient 63 had a KRAS G12V, SMAD4, GNAS, and KMT2C mutant-positive PDAC with liver metastases while Patient 64′s cancer was BRAF V600E-positive, and they had also undergone treatment with experimental BRAF and MEK inhibitors (Figure S3E).